Elevate Health review

Elevate Health offers a direct NAD⁺ injection entry with $167 under Monthly Subscription and $293 one-time under a 3 Month plan. That is a useful price display, but it leaves quantity, strength, fulfillment and the complete charge unconfirmed. No GLP-1 prerequisite appears on the initial screen; later eligibility or bundle conditions remain unclear. Its policy includes automatic billing, a possible $150 early-cancellation fee and a pharmacy-transmission refund cutoff. Injected NAD⁺ has no controlled outcome trials behind the energy and longevity claims.

Elevate Health, operated by Elevate Health and Wellness LLC, is a patient-management platform supporting physicians contracted through MDIntegrations and TelegraMD. Its medical weight-loss line includes compounded semaglutide and tirzepatide alongside brand-name Zepbound. The homepage also offers a direct NAD⁺ injection entry separate from GLP-1 selection, alongside B12 and glutathione promotion. It displays a LegitScript seal and advertises supplies, a free lab panel, HSA/FSA use and Affirm or Klarna financing; those claims do not establish insurance coverage or the contents of a particular NAD⁺ order.

The named MDIntegrations and TelegraMD networks handle prescribing if appropriate. NAD⁺ has its own initial plan screen, but subsequent eligibility and any other program requirement are unconfirmed. The policy requires adults aged 18 or older and says a 503A pharmacy is assigned according to state; the pharmacy can be requested through consultation or support, and patients may choose another. No named dispenser or state list is provided. The weight-program BMI criteria apply to that program, not automatically to NAD⁺. Usual delivery is advertised at seven to ten business days after approval. Commercial terms sit within the Privacy policy: automatic charges follow intervals specified for the selected plan, and the total bundles platform, provider and pharmacy services. Support can process cancellation, but the FAQ excludes the 12 Week Program; abandoning a signup or refill form does not cancel. Privacy terms describe affiliate, provider and service-provider sharing while saying personal data is not sold, rented or leased.

The NAD⁺ injection screen displays $167 monthly under Monthly Subscription and $293 one-time under a 3 Month plan. The latter is not a one-month offer or an established recurring monthly rate; its label does not confirm three months of dispensed medication. Strength, quantity, supply, exact first debit and later renewal terms remain unconfirmed. Semaglutide displays $139 monthly subscription or $99 monthly equivalents on three-, six- and twelve-month plans; tirzepatide displays $169 and $149 respectively. Those equivalents do not establish upfront totals or dispensing frequency. The advertised $200 discount is not confirmed to combine with these rates. Cancellation within 24 hours of payment is allowed only if processing has not started; after assessment begins a $150 early-cancellation fee applies, and no refund is available after transmission to the fulfillment pharmacy. The homepage separately promises a full refund for medical ineligibility; obtain the applicable terms for your order.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Elevate displays the disclaimer directly: its own copy says compounded medications are not FDA-approved and the FDA does not verify their safety, effectiveness or quality, and that treatment decisions are made solely by a licensed provider. Its pharmacies are described as state-licensed but not named, and compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are. On evidence, the NAD⁺ framing needs a direct answer. It is marketed here for "energy and longevity", and there are no controlled human outcome trials supporting either claim for injected NAD⁺; the single human intravenous study was a pharmacokinetic pilot that found infused NAD⁺ clears from plasma quickly. The NAD⁺ evidence that exists sits with the oral precursors NR and NMN, which reliably raise blood NAD⁺, a biomarker rather than a demonstrated clinical outcome. Glutathione, also listed as an add-on, has essentially no controlled human outcome evidence either. The brand-name Zepbound it offers is an approved product. Individual results vary.